Center for Joint Regeneration Now Offering Outpatient Stem Cell Procedures for Arthritis, Tendonitis and Ligament …

Phoenix, Arizona (PRWEB) April 14, 2014

The top orthopedic stem cell clinic in Arizona, Center for Joint Regeneration, is now offering stem cell procedures for arthritis, tendonitis and ligament injuries. The procedures have the ability to provide pain relief and help patients avoid the need for joint replacement or soft tissue surgery. For more information and scheduling, call (480) 466-0980.

There are two Board Certified, Fellowship Trained Orthopedic Doctors at the Center for Joint Regeneration. Drs. Adam Farber and Sumit Dewanjee offer stem cell procedures for all types of joint arthritis along with soft tissue injuries. This includes hip, knee and shoulder arthritis along with rotator cuff tendonitis and tears, knee injuries and elbow tendonitis.

The stem cell procedures involve either bone marrow derived material from the patient or amniotic derived stem cells. The bone marrow stem cell procedure is performed as an outpatient and maintains low risk. The amniotic material is processed at an FDA regulated lab, and has been shown to have the capability to regenerate soft tissues and cartilage.

Patients receiving the procedures have often been able to get back to sports activities faster than otherwise, and delay or avoid the need for joint replacement surgery of the hip, knee or shoulder. In addition, rotator cuff tendonitis and tears often does extremely well with the stem cell procedures.

Appointments are readily available with the Board Certified Phoenix orthopedic doctors to discuss available options for stem cell procedures. Call (480) 466-0980 for more information and scheduling with the Center for Joint Regeneration.

See the original post here:
Center for Joint Regeneration Now Offering Outpatient Stem Cell Procedures for Arthritis, Tendonitis and Ligament ...

Valley Foot Surgeons Joins R3 Stem Cell, Now Offering Stem Cell Procedures for All Foot and Ankle Conditions

Scottsdale, AZ (PRWEB) April 14, 2014

Valley Foot Surgeons, the top foot and ankle doctors in Phoenix, have joined the R3 Stem Cell network and are now offering several types of stem cell procedures. The stem cell procedures are performed by Dr. Richard Jacoby, 4 time winner of the Phoenix Top Doc Award. Call (480) 420-3499 for more information and scheduling.

Stem cell procedures for foot and ankle conditions are becoming more popular for several reasons. Plantar fasciitis, for instance, may bother patients for months and does not have an acceptable surgical solution. Stem cells for plantar fasciitis may provide pain relief and regeneration of the damaged tissue, while helping patients avoid surgery most of the time.

Achilles tendonitis and tears present a quandary to both patients and doctors. Surgery entails significant rehabilitation and risk, so it is best to avoid it if at all possible. Dr. Jacoby has performed close to a hundred stem cell procedures for achilles tendonitis and tears. The results have been extremely impressive, with the vast majority of patients achieving pain relief and avoiding the need for an operation.

Along with plantar fasciitis and achilles conditions, the stem cell procedures work exceptionally well for diabetic wounds. This also includes crush injuries and difficult to heal wounds.

All of the stem cell procedures are performed as an outpatient by Dr. Richard Jacoby. He has been a practicing foot and ankle specialist for over two decades, providing cutting edge procedures such as regenerative medicine injections.

For those who have a foot and ankle condition such as arthritis, tendonitis, plantar fasciitis,or a difficult to heal wound, Valley Foot Surgeons can help patients with pain relief and surgery avoidance. Call (480) 420-3499 for more information and scheduling.

View post:
Valley Foot Surgeons Joins R3 Stem Cell, Now Offering Stem Cell Procedures for All Foot and Ankle Conditions

How a Silly Putty ingredient could advance stem cell therapies

14 hours ago University of Michigan researchers have found that mechanical forces in the environment of human embryonic stem cells influences how they differentiate, or morph into the body's different cell types. To arrive at the findings, they cultured the stem cells on ultrafine carpets made of microscopic posts of a key ingredient in Silly Putty. Credit: Ye Tao, Rose Anderson, Yubing Sun, and Jianping Fu.

The sponginess of the environment where human embryonic stem cells are growing affects the type of specialized cells they eventually become, a University of Michigan study shows.

The researchers coaxed human embryonic stem cells to turn into working spinal cord cells more efficiently by growing the cells on a soft, utrafine carpet made of a key ingredient in Silly Putty. Their study is published online at Nature Materials on April 13.

This research is the first to directly link physical, as opposed to chemical, signals to human embryonic stem cell differentiation. Differentiation is the process of the source cells morphing into the body's more than 200 cell types that become muscle, bone, nerves and organs, for example.

Jianping Fu, U-M assistant professor of mechanical engineering, says the findings raise the possibility of a more efficient way to guide stem cells to differentiate and potentially provide therapies for diseases such as amyotrophic lateral sclerosis (Lou Gehrig's disease), Huntington's or Alzheimer's.

In the specially engineered growth systemthe 'carpets' Fu and his colleagues designedmicroscopic posts of the Silly Putty component polydimethylsiloxane serve as the threads. By varying the post height, the researchers can adjust the stiffness of the surface they grow cells on. Shorter posts are more rigidlike an industrial carpet. Taller ones are softermore plush.

The team found that stem cells they grew on the tall, softer micropost carpets turned into nerve cells much faster and more often than those they grew on the stiffer surfaces. After 23 days, the colonies of spinal cord cellsmotor neurons that control how muscles movethat grew on the softer micropost carpets were four times more pure and 10 times larger than those growing on either traditional plates or rigid carpets.

"This is extremely exciting," Fu said. "To realize promising clinical applications of human embryonic stem cells, we need a better culture system that can reliably produce more target cells that function well. Our approach is a big step in that direction, by using synthetic microengineered surfaces to control mechanical environmental signals."

Fu is collaborating with doctors at the U-M Medical School. Eva Feldman, the Russell N. DeJong Professor of Neurology, studies amyotrophic lateral sclerosis, or ALS. It paralyzes patients as it kills motor neurons in the brain and spinal cord.

Researchers like Feldman believe stem cell therapiesboth from embryonic and adult varietiesmight help patients grow new nerve cells. She's using Fu's technique to try to make fresh neurons from patients' own cells. At this point, they're examining how and whether the process could work, and they hope to try it in humans in the future.

Read more here:
How a Silly Putty ingredient could advance stem cell therapies

NBI files raps vs Arroyo's 'fake' stem cell doc

MANILA - The National Bureau of Investigation-Anti-Organized and Transnational Crime Division (NBI-AOTCD) has filed a case against an allegedly fake doctor who once administered stem cell therapy on former President Gloria Macapagal Arroyo.

Members of the NBI-AOCTD, headed by Head Agent Rommel J. Vallejo, acted on the complaint filed by Dr. Eunice Salazar-Abad, who worked as an aesthetic physician for Antonia Carandang-Park.

The latter is the owner of Green and Young Health and Wellness Center based in San Jose, Tagaytay City.

Vallejo said: Even for a short period of time working at the clinic, she began to notice some irregularities and the unorthodox method being applied by Park in treating the patients. She discovered too, that Park is using her name and her license number in dealing with patients.

Salazar-Abad then verified with the Professional Regulation Commission to check if Park is a licensed doctor,

Based on a document dated August 12, 2013, the PRC certified that after a diligent search, the name Antonia Carandang Park does not appear in the database of Physician, which contains the names of those duly authorized to practice medicine in the Philippines.

The document reads, this certification is issued upon request of the Board of Medicine for whatever legal purpose it may serve.

Park gained popularity when she treated Arroyo, who had been complaining of pains due to a cervical spine surgery.

Salazar-Abad noted Park did not make any effort to speak up when reports tagged her as a doctor. She said Park also misrepresented herself as an oncologist.

Vallejo said Park filed her counter-affidavit on August 22, saying she is not a quack doctor.

Read the original:
NBI files raps vs Arroyo's 'fake' stem cell doc

Umbilical Cord Stem Cell Therapy Clinical Trial for Multiple Sclerosis Gets Green Light

Dallas, TX (PRWEB) April 03, 2014

Translational Biosciences, a subsidiary of Medistem Panama, has received the green light for a phase I/II clinical trial using human umbilical cord-derived mesenchymal stem cells (UC-MSC) for multiple sclerosis from the Comit Nacional de Biotica de la Investigacin (CNEI) Institutional Review Board (IRB) in Panama.

According to the US National Multiple Sclerosis Society, in Multiple Sclerosis (MS), an abnormal immune-mediated T cell response attacks the myelin coating around nerve fibers in the central nervous system, as well as the nerve fibers themselves. This causes nerve impulses to slow or even halt, thus producing symptoms of MS that include fatigue; bladder and bowel problems; vision problems; and difficulty walking. The Cleveland Clinic reports that MS affects more than 350,000 people in the United States and 2.5 million worldwide.

Mesenchymal stem cells harvested from donated human umbilical cords after normal, healthy births possess anti-inflammatory and immune modulatory properties that may relieve MS symptoms. Because these cells are immune privileged, the recipients immune system does not reject them. These properties make UC-MSC interesting candidates for the treatment of multiple sclerosis and other autoimmune disorders.

Each patient will receive seven intravenous injections of UC-MSC over the course of 10 days. They will be assessed at 3 months and 12 months primarily for safety and secondarily for indications of efficacy.

The stem cell technology being utilized in this trial was developed by Neil Riordan, PhD, founder of Medistem Panama. The stem cells will be harvested and processed at Medistem Panamas 8000 sq. ft. ISO-9001 certified laboratory in the prestigious City of Knowledge. They will be administered at the Stem Cell Institute in Panama City, Panama.

From his research laboratory in Dallas, Texas, Dr. Riordan commented, Umbilical cord tissue provides an abundant, non-controversial supply of immune modulating mesenchymal stem cells. Preclinical and clinical research has demonstrated the anti-inflammatory and immune modulating effects of these cells. We look forward to the safety and efficacy data that will be generated by this clinical trial; the first in the western hemisphere testing the effects of umbilical cord mesenchymal stem cells on patients with multiple sclerosis.

The Principle Investigator is Jorge Paz-Rodriguez, MD. Dr. Paz-Rodriguez also serves as the Medical Director at the Stem Cell Institute.

For detailed information about this clinical trial visit http://www.clinicaltrials.gov . If you are a multiple sclerosis patient between the ages of 18 and 55, you may qualify for this trial. Please email trials (at) translationalbiosciences (dot) com for more information about how to apply.

About Translational Biosciences

See the rest here:
Umbilical Cord Stem Cell Therapy Clinical Trial for Multiple Sclerosis Gets Green Light

Stem cell tourism takes advantage of patients, says law professor

Patients falling prey to 'stem cell tourism' may pay tens of thousands of dollars for procedures that carry no promise of success or carry grievous risks of failure, says law and bioethics Professor Alta Charo.

Photo illustration: iStock

Desperate patients are easy prey for unscrupulous clinics offering untested and risky stem cell treatments, says UW-Madison law and bioethics Professor Alta Charo, who is studying "stem cell tourism."

Stem cells are cells that can form many types of cells in the body, and that makes them inherently promising and dangerous. "Stem cell tourism" refers to people traveling, both within the U.S. and abroad, in pursuit of advertised stem cell therapies to purportedly treat a variety of medical conditions.

Alta Charo

"The evidence for therapeutic use of stem cells is very limited, except for bone marrow stem cells, but patients all over the world are convinced stem cells will cure their disease," says Charo. "While there are some very promising results in the early clinical trials for stem cell therapies using embryonic and other kinds of stem cells, the 'treatments' being advertised by these clinics are dubious, mostly ineffective, and sometimes positively harmful.

"Patients are being hoodwinked, but there are dilemmas about tackling (the 'treatments') at regulatory or political levels."

The outrage over failures in stem cell tourism is limited, Charo says. Patients may pay tens of thousands of dollars for procedures that may carry no promise of success or carry grievous risks of failure. "Most people have no reason to pay attention, and those who are paying attention are sick, so they are focused on trying anything," Charo says. "If it does not work, they are already in a bad position with plenty to think about."

Go here to read the rest:
Stem cell tourism takes advantage of patients, says law professor

Adjustable scaffold tunes stem cell growth

A new scaffold material based on a biocompatible silk-alginate hydrogel, which can be made soft or stiff, could provide the just right environment to culture stem cells for regenerative medicine, say researchers.

Stem cells could provide powerful new treatments for intractable autoimmune diseases, cancer, and other conditions. But the use of stem cells in the clinic requires a robust and reliable culture system that mimics the natural microenvironment of the cell. This microenvironment provides crucial direction to the function and viability of stem cells but is tricky to recreate artificially.

The complex make-up of the microenvironment, which includes a network of proteins like collagen or elastins forming an extracellular matrix (ECM), decides the fate of stem cells through a number of different, complementary mechanisms. For example, the stiffness of the matrix, determined by the orientation and elasticity of the fibers making up the ECM, as well as its fluid handling properties, the presence of signaling molecules and the creation of cytokine gradients all have a profound effect on the growing stem cells.

The new silk-alginate biocomposite developed by researchers at Stanford University and Queens University in Canada could provide a simple solution to tackle these complex problems. The hydrogel is formed from a mixture of alginate and silk in solution, which rapidly gels when immersed in CaCl2 [Ziv, et al., Biomaterials 35 (2014) 3736-3743, http://dx.doi.org/10.1016/j.biomaterials.2014.01.029%5D. But crucially, the stable hydrogel can be made soft and flexible or stiff by controlling the silk-alginate ratio and the concentration of crosslinking ions. Varying the silk-alginate ratio during fabrication changes the elasticity of the hydrogel, which can determine the yield of a particular differentiation path. The elasticity can be further fine-tuned in vitro by varying the CaCl2 concentration. Being able to modify the stiffness of the scaffold material to such a degree gives researchers a powerful means of guiding stem cell survival and differentiation.

The ability to change the elasticity [of the silk-alginate hydrogel] helps mimic the natural process that is happening in the stem cell niche and improves the stem cell commitment into desired differentiation paths, explains first author Keren Ziv, of the Molecular Imaging Program at Stanford.

Using the protein laminin to enhance cell adhesion and promote cell growth, the researchers cultured mouse embryonic stem cells in the new scaffold material and transplanted samples into live mice. The silk-alginate hydrogel appears to be better at maintaining the survival of stem cells once transplanted than the best current alternative, matrigel.

But there is a long way to go until the new scaffold material could be used in the clinic for stem cell applications, cautions Ziv. Ideally, such applications would require the injection of the hydrogel in liquid form followed by gelation but this is currently unfeasible in vivo. The long-term stability of the hydrogel also needs to be scrutinized, along with its effect on other cell types. These issues are tractable, however, say the researchers, and are the focus of on-going efforts.

Read more:
Adjustable scaffold tunes stem cell growth

New Method Makes Muscle Cells From Human Stem Cells

March 24, 2014

Image Caption: Muscle cells are stained green in this micrograph of cells grown from embryonic stem cells in the lab of Masatoshi Suzuki at the University of Wisconsin -- Madison. Cell nuclei are stained blue; the muscle fibers contain multiple nuclei. Nuclei outside the green fibers are from non-muscle cells. Suzuki has developed a new method of growing stem cells into muscle cells that could be more suitable for treating disease. Suzuki hopes to experiment next with animals that model muscular dystrophy and amyotrophic lateral sclerosis. Credit: Masatoshi Suzuki

David Tenenbaum, University of Wisconsin-Madison

As stem cells continue their gradual transition from the lab to the clinic, a research group at the University of Wisconsin-Madison has discovered a new way to make large concentrations of skeletal muscle cells and muscle progenitors from human stem cells.

The new method, described in the journal Stem Cells Translational Medicine, could be used to generate large numbers of muscle cells and muscle progenitors directly from human pluripotent stem cells. These stem cells, such as embryonic (ES) or induced pluripotent stem (iPS) cells, can be made into virtually any adult cell in the body.

Adapting a method previously used to make brain cells, Masatoshi Suzuki, an assistant professor of comparative biosciences in the School of Veterinary Medicine, has directed those universal stem cells to become both adult muscle cells and muscle progenitors.

Importantly, the new technique grows the pluripotent stem cells as floating spheres in high concentrations of two growth factors, fibroblast growth factor-2 and epidermal growth factor. These growth factors urge the stem cells to become muscle cells.

Researchers have been looking for an easy way to efficiently differentiate stem cells into muscle cells that would be allowable in the clinic, says Suzuki. The novelty of this technique is that it generates a larger number of muscle stem cells without using genetic modification, which is required by existing methods for making muscle cells.

Many other protocols have been used to enhance the number of cells that go to a muscle fate, says co-author Jonathan Van Dyke, a post-doctoral fellow in Suzukis laboratory. But whats exciting about the new protocol is that we avoid some techniques that would prohibit clinical applications. We think this new method has great promise for alleviating human suffering.

Last year, Suzuki demonstrated that transplants of another type of human stem cells somewhat improved survival and muscle function in rats that model amyotrophic lateral sclerosis (ALS). Also known as Lou Gehrigs disease, ALS destroys nerves and causes a loss of muscle control. The muscle progenitors generated with Suzukis new method could potentially play a similar role but with enhanced effect.

See more here:
New Method Makes Muscle Cells From Human Stem Cells

New way to make muscle cells from human stem cells

As stem cells continue their gradual transition from the lab to the clinic, a research group at the University of Wisconsin-Madison has discovered a new way to make large concentrations of skeletal muscle cells and muscle progenitors from human stem cells.

The new method, described in the journal Stem Cells Translational Medicine, could be used to generate large numbers of muscle cells and muscle progenitors directly from human pluripotent stem cells. These stem cells, such as embryonic (ES) or induced pluripotent stem (iPS) cells, can be made into virtually any adult cell in the body.

Adapting a method previously used to make brain cells, Masatoshi Suzuki, an assistant professor of comparative biosciences in the School of Veterinary Medicine, has directed those universal stem cells to become both adult muscle cells and muscle progenitors.

Importantly, the new technique grows the pluripotent stem cells as floating spheres in high concentrations of two growth factors, fibroblast growth factor-2 and epidermal growth factor. These growth factors "urge" the stem cells to become muscle cells.

"Researchers have been looking for an easy way to efficiently differentiate stem cells into muscle cells that would be allowable in the clinic," says Suzuki. The novelty of this technique is that it generates a larger number of muscle stem cells without using genetic modification, which is required by existing methods for making muscle cells.

"Many other protocols have been used to enhance the number of cells that go to a muscle fate," says co-author Jonathan Van Dyke, a post-doctoral fellow in Suzukis laboratory. "But what's exciting about the new protocol is that we avoid some techniques that would prohibit clinical applications. We think this new method has great promise for alleviating human suffering."

Last year, Suzuki demonstrated that transplants of another type of human stem cells somewhat improved survival and muscle function in rats that model amyotrophic lateral sclerosis (ALS). Also known as Lou Gehrig's disease, ALS destroys nerves and causes a loss of muscle control. The muscle progenitors generated with Suzukis new method could potentially play a similar role but with enhanced effect.

The new technique can also be used to grow muscle cells from iPS cells from patients with neuromuscular diseases like ALS, spinal muscular atrophy and muscular dystrophy. Thus, the technique could produce adult muscle cells in a dish that carry genetic diseases. These cells could then be used as a tool for studying these diseases and screening potential drug compounds, says Suzuki. "Our protocol can work in multiple ways and so we hope to provide a resource for people who are exploring specific neuromuscular diseases in the laboratory."

The new protocol incorporates a number of advantages. First, the cells are grown in defined supplements without animal products such as bovine serum, enhancing the clinical safety for the muscle stem cells. Second, when grown as spheres, the cells grow faster than with previous techniques. Third, 40 to 60 percent of the cells grown using the process are either muscle cells or muscle progenitors, a high proportion compared to traditional non-genetic techniques of generating muscle cells from human ES and iPS cells.

Suzuki and his group hope that by further manipulating the chemical environment of the spheres of stem cells, they may increase that number, further easing the path toward human treatment.

See more here:
New way to make muscle cells from human stem cells

A New Way to Make Muscle Cells From Human Stem Cells

Contact Information

Available for logged-in reporters only

Note: A high-resolution photo to accompany this release is available at http://www.news.wisc.edu/newsphotos/masatoshiSuzuki_13.html

Newswise MADISON, Wis. As stem cells continue their gradual transition from the lab to the clinic, a research group at the University of Wisconsin-Madison has discovered a new way to make large concentrations of skeletal muscle cells and muscle progenitors from human stem cells.

The new method, described in the journal Stem Cells Translational Medicine, could be used to generate large numbers of muscle cells and muscle progenitors directly from human pluripotent stem cells. These stem cells, such as embryonic (ES) or induced pluripotent stem (iPS) cells, can be made into virtually any adult cell in the body.

Adapting a method previously used to make brain cells, Masatoshi Suzuki, an assistant professor of comparative biosciences in the School of Veterinary Medicine, has directed those universal stem cells to become both adult muscle cells and muscle progenitors.

Importantly, the new technique grows the pluripotent stem cells as floating spheres in high concentrations of two growth factors, fibroblast growth factor-2 and epidermal growth factor. These growth factors "urge" the stem cells to become muscle cells.

"Researchers have been looking for an easy way to efficiently differentiate stem cells into muscle cells that would be allowable in the clinic," says Suzuki. The novelty of this technique is that it generates a larger number of muscle stem cells without using genetic modification, which is required by existing methods for making muscle cells.

"Many other protocols have been used to enhance the number of cells that go to a muscle fate," says co-author Jonathan Van Dyke, a post-doctoral fellow in Suzukis laboratory. "But what's exciting about the new protocol is that we avoid some techniques that would prohibit clinical applications. We think this new method has great promise for alleviating human suffering."

Last year, Suzuki demonstrated that transplants of another type of human stem cells somewhat improved survival and muscle function in rats that model amyotrophic lateral sclerosis (ALS). Also known as Lou Gehrig's disease, ALS destroys nerves and causes a loss of muscle control. The muscle progenitors generated with Suzukis new method could potentially play a similar role but with enhanced effect.

Read the original here:
A New Way to Make Muscle Cells From Human Stem Cells